MA28215A1 - Galenic forms of oxycodone controlled release for once-daily oral administration - Google Patents
Galenic forms of oxycodone controlled release for once-daily oral administrationInfo
- Publication number
- MA28215A1 MA28215A1 MA28979A MA28979A MA28215A1 MA 28215 A1 MA28215 A1 MA 28215A1 MA 28979 A MA28979 A MA 28979A MA 28979 A MA28979 A MA 28979A MA 28215 A1 MA28215 A1 MA 28215A1
- Authority
- MA
- Morocco
- Prior art keywords
- profiles
- once
- galenic forms
- oral administration
- controlled release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
FORMES GALÉNIQUES DE L'OXYCODONE À LIBÉRATION CONTRÔLÉE POUR ADMINISTRATION ORALE UNE FOIS PAR JOUR La présente invention concerne des formulations d'oxycodone qui produisent des profils plasma tiques en équilibre dynamique in vivo pratiquement plats. Les niveaux de tolérance associés à de tels profils et les niveaux de tolérance associés aux profils biphasiques se sont révélés ne pas être statistiquement différents. Les profils p.iasmatiques en équilibre dynamique in vivo pratiquement plats sont produits par des formes galéniques ayant des profils de libération in vit.ro pratiquement de l'ordre de zéro. De tels prot ils de libération produisent des niveaux faibles de Cmaz in vivo avec une dose unique qui peuvent diminuer la probabilité des effets secondaires néfastes.The present invention relates to oxycodone formulations that produce substantially in vivo dynamic equilibrium plasma profiles in practically flat equilibrium. The tolerance levels associated with such profiles and the tolerance levels associated with biphasic profiles have been shown not to be statistically different. The substantially in vivo dynamic equilibrium p.iasmatic profiles are produced by galenic forms having in vitro release profiles of substantially zero order. Such release proteins produce low levels of Cmaz in vivo with a single dose that may decrease the likelihood of adverse side effects.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51588003P | 2003-10-29 | 2003-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28215A1 true MA28215A1 (en) | 2006-10-02 |
Family
ID=34549453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28979A MA28215A1 (en) | 2003-10-29 | 2006-04-28 | Galenic forms of oxycodone controlled release for once-daily oral administration |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1677798A2 (en) |
JP (1) | JP2007509979A (en) |
KR (1) | KR20060108690A (en) |
CN (1) | CN1933837A (en) |
AU (1) | AU2004285547A1 (en) |
BR (1) | BRPI0415639A (en) |
CA (1) | CA2546691A1 (en) |
EC (1) | ECSP066534A (en) |
IL (1) | IL175193A0 (en) |
MA (1) | MA28215A1 (en) |
NO (1) | NO20062398L (en) |
RU (1) | RU2006118323A (en) |
WO (1) | WO2005041968A2 (en) |
ZA (1) | ZA200604310B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE526950T1 (en) | 1999-10-29 | 2011-10-15 | Euro Celtique Sa | CONTROLLED RELEASE HYDROCODONE FORMULATIONS |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
WO2002036099A1 (en) | 2000-10-30 | 2002-05-10 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
UA81224C2 (en) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Dosage form of oxycodone and use thereof |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE102004032051A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
DE102007011485A1 (en) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
JP5774853B2 (en) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Pharmaceutical dosage form |
US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
CA2723438C (en) | 2008-05-09 | 2016-10-11 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
MX2012000317A (en) | 2009-07-22 | 2012-02-08 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form. |
MX2012000369A (en) | 2009-07-22 | 2012-02-01 | Gruenenthal Gmbh | Tamper-resistant dosage form for oxidation-sensitive oploids. |
US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
EP2555756B1 (en) * | 2010-04-07 | 2018-08-22 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
RU2604676C2 (en) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Destruction-resistant dosage form containing an inorganic salt |
ES2487244T3 (en) | 2010-09-02 | 2014-08-20 | Grünenthal GmbH | Handling resistant dosage form comprising an anionic polymer |
PT2736495T (en) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US20130028972A1 (en) | 2011-07-29 | 2013-01-31 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
BR112014019988A8 (en) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | BREAK-RESISTANT DOSAGE FORM COMPRISING A PHARMACOLOGICALLY ACTIVE COMPOUND AND AN ANIONIC POLYMER |
JP6282261B2 (en) | 2012-04-18 | 2018-02-21 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Unauthorized use and overdose prevention pharmaceutical dosage forms |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
BR112015029616A2 (en) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | tamper-resistant dosage form with bimodal release profile |
CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
KR20160031526A (en) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
MX371372B (en) | 2013-11-26 | 2020-01-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling. |
CA2947786A1 (en) | 2014-05-12 | 2015-11-19 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol |
WO2015181059A1 (en) | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
CN107889459A (en) | 2015-04-24 | 2018-04-06 | 格吕伦塔尔有限公司 | Tamper resistant dosage form with release immediately and to solvent-extracted resistance |
AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
TW202329972A (en) | 2016-08-10 | 2023-08-01 | 瑞士商赫孚孟拉羅股份公司 | Pharmaceutical compositions comprising akt protein kinase inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914131A (en) * | 1994-07-07 | 1999-06-22 | Alza Corporation | Hydromorphone therapy |
UA81224C2 (en) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Dosage form of oxycodone and use thereof |
US20040010000A1 (en) * | 2002-04-29 | 2004-01-15 | Ayer Atul D. | Methods and dosage forms for controlled delivery of oxycodone |
MXPA04012021A (en) * | 2002-05-31 | 2005-08-16 | Johnson & Johnson | Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone. |
-
2004
- 2004-10-28 CN CNA2004800394188A patent/CN1933837A/en active Pending
- 2004-10-28 RU RU2006118323/15A patent/RU2006118323A/en unknown
- 2004-10-28 KR KR1020067010336A patent/KR20060108690A/en not_active Application Discontinuation
- 2004-10-28 JP JP2006538357A patent/JP2007509979A/en not_active Withdrawn
- 2004-10-28 EP EP04817492A patent/EP1677798A2/en not_active Withdrawn
- 2004-10-28 WO PCT/US2004/036132 patent/WO2005041968A2/en active Application Filing
- 2004-10-28 BR BRPI0415639-0A patent/BRPI0415639A/en not_active IP Right Cessation
- 2004-10-28 AU AU2004285547A patent/AU2004285547A1/en not_active Abandoned
- 2004-10-28 CA CA002546691A patent/CA2546691A1/en not_active Abandoned
-
2006
- 2006-04-25 IL IL175193A patent/IL175193A0/en unknown
- 2006-04-28 MA MA28979A patent/MA28215A1/en unknown
- 2006-04-28 EC EC2006006534A patent/ECSP066534A/en unknown
- 2006-05-26 NO NO20062398A patent/NO20062398L/en not_active Application Discontinuation
- 2006-05-26 ZA ZA200604310A patent/ZA200604310B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP066534A (en) | 2006-11-24 |
CA2546691A1 (en) | 2005-05-12 |
WO2005041968A2 (en) | 2005-05-12 |
RU2006118323A (en) | 2007-12-10 |
AU2004285547A1 (en) | 2005-05-12 |
CN1933837A (en) | 2007-03-21 |
KR20060108690A (en) | 2006-10-18 |
ZA200604310B (en) | 2007-11-28 |
JP2007509979A (en) | 2007-04-19 |
EP1677798A2 (en) | 2006-07-12 |
NO20062398L (en) | 2006-07-27 |
IL175193A0 (en) | 2008-04-13 |
WO2005041968A3 (en) | 2006-06-22 |
BRPI0415639A (en) | 2006-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28215A1 (en) | Galenic forms of oxycodone controlled release for once-daily oral administration | |
MA38576A1 (en) | Colchicine extended-release formulations and methods of using the same | |
RS20110564A2 (en) | Diurnal formulation of oxycodone | |
BR0008059A (en) | Compositions of valdecoxib | |
NO20052739L (en) | CCR5 antagonists as drugs | |
WO2003070236A3 (en) | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | |
WO2004054581A3 (en) | Cyclohexyl compounds as ccr5 antagonists | |
EP1820503A3 (en) | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
DE60021749D1 (en) | PHARMACEUTICAL FORMULATION CONTAINING TOLTERODINE AND ITS USE | |
CY1105648T1 (en) | FILBANSERIN FOR THE TREATMENT OF EXTRAPYRAMIDAL MOVEMENT DISORDERS | |
ATE407928T1 (en) | AMINO-PHTALAZINONE DERIVATIVES, USE AS KINASE INHIBITORS, PRODUCTION AND PHARMACEUTICAL COMPOSITION | |
MA31668B1 (en) | POLYPEPTIDES, VARIOUS DOMAINS OF ANTIBODIES AND ANTAGONISTS | |
TNSN07476A1 (en) | N- (PYRIDINE -2- YL) - SULFONAMIDE DERIVATIVES | |
WO2008019996A3 (en) | Formulations of flibanserin and method for manufacturing the same | |
HK1087336A1 (en) | Pharmaceutical composition comprising lumiracoxib | |
AU2003296992A1 (en) | Pyrrolidine and azetidine compounds as ccr5 antagonists | |
SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
HRP20080612T3 (en) | Combination of tenofovir, ritonavir and tmc114 | |
JP2008540405A5 (en) | ||
MA29278B1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING AN INDOLYLMALEIMIDE DERIVATIVE | |
MXPA05009719A (en) | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them. | |
MXPA03010054A (en) | Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents. | |
WO2004064757A3 (en) | Absorption enhancing agents | |
WO2023114943A3 (en) | Lipids for use in lipid nanoparticle formulations | |
DK1653923T3 (en) | Oral delivery system comprising a biliary foam |